Genotype-Clinical Correlations in Polycystic Kidney Disease with No Apparent Family History.


Journal

American journal of nephrology
ISSN: 1421-9670
Titre abrégé: Am J Nephrol
Pays: Switzerland
ID NLM: 8109361

Informations de publication

Date de publication:
2019
Historique:
received: 13 11 2018
accepted: 03 01 2019
pubmed: 2 3 2019
medline: 12 5 2020
entrez: 2 3 2019
Statut: ppublish

Résumé

Genetic characteristics of polycystic kidney disease (PKD) patients without apparent family history were reported to be different from those with a positive family history. However, the clinical course of PKD patients with no apparent family history is not well documented in the literature. We evaluated the relationship between genotype and the clinical course of 62 PKD patients with no apparent family history. The annual decline of renal function was faster in the patients with PKD1/PKD2 mutation (PKD1 truncating [-3.08; 95% CI -5.30 to -0.87, p = 0.007], PKD1 nontruncating [-2.10; -3.82 to -0.38, p = 0.02], and PKD2 [-2.31; -4.40 to -0.23, p = 0.03]) than in the other patients without PKD1/PKD2 mutation. Similar results were obtained after adjustment for gender, age, estimated glomerular filtration rate (eGFR), height-adjusted total kidney volume (TKV), and mean arterial pressure (MAP). There was no significant difference in the annual decline of renal function among the different PKD1/PKD2 groups, but Kaplan-Meier analysis showed that progression to eGFR < 15 mL/min/1.73 m2 was significantly faster in PKD1 truncating group (p = 0.05). The annual rate of TKV increase was larger in the patients with PKD1/PKD2 mutation (PKD1 truncating [4.63; 95% CI 0.62-8.64, p = 0.03], PKD1 nontruncating [3.79; 0.55-7.03, p = 0.02], and PKD2 [2.11; -1.90 to 6.12, p = 0.29]) than in the other patients without PKD1/PKD2 mutation. Similar results were obtained after adjustment for gender, age, eGFR, and MAP. Detection of PKD1/PKD2 mutation, especially PKD1 truncating, is useful for predicting the renal outcome and rate of TKV increase in PKD patients with no apparent family history.

Sections du résumé

BACKGROUND
Genetic characteristics of polycystic kidney disease (PKD) patients without apparent family history were reported to be different from those with a positive family history. However, the clinical course of PKD patients with no apparent family history is not well documented in the literature.
METHODS
We evaluated the relationship between genotype and the clinical course of 62 PKD patients with no apparent family history.
RESULTS
The annual decline of renal function was faster in the patients with PKD1/PKD2 mutation (PKD1 truncating [-3.08; 95% CI -5.30 to -0.87, p = 0.007], PKD1 nontruncating [-2.10; -3.82 to -0.38, p = 0.02], and PKD2 [-2.31; -4.40 to -0.23, p = 0.03]) than in the other patients without PKD1/PKD2 mutation. Similar results were obtained after adjustment for gender, age, estimated glomerular filtration rate (eGFR), height-adjusted total kidney volume (TKV), and mean arterial pressure (MAP). There was no significant difference in the annual decline of renal function among the different PKD1/PKD2 groups, but Kaplan-Meier analysis showed that progression to eGFR < 15 mL/min/1.73 m2 was significantly faster in PKD1 truncating group (p = 0.05). The annual rate of TKV increase was larger in the patients with PKD1/PKD2 mutation (PKD1 truncating [4.63; 95% CI 0.62-8.64, p = 0.03], PKD1 nontruncating [3.79; 0.55-7.03, p = 0.02], and PKD2 [2.11; -1.90 to 6.12, p = 0.29]) than in the other patients without PKD1/PKD2 mutation. Similar results were obtained after adjustment for gender, age, eGFR, and MAP.
CONCLUSION
Detection of PKD1/PKD2 mutation, especially PKD1 truncating, is useful for predicting the renal outcome and rate of TKV increase in PKD patients with no apparent family history.

Identifiants

pubmed: 30820006
pii: 000497444
doi: 10.1159/000497444
doi:

Substances chimiques

TRPP Cation Channels 0
polycystic kidney disease 1 protein 0
polycystic kidney disease 2 protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-240

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Akinari Sekine (A)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Takuya Fujimaru (T)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Junichi Hoshino (J)

Nephrology Center, Toranomon Hospital, Tokyo, Japan, hoshino@toranomon.gr.jp.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan, hoshino@toranomon.gr.jp.

Tatsuya Suwabe (T)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Masahiko Oguro (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Hiroki Mizuno (H)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Masahiro Kawada (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Keiichi Sumida (K)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Rikako Hiramatsu (R)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Eiko Hasegawa (E)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Masayuki Yamanouchi (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Noriko Hayami (N)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Shintaro Mandai (S)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Motoko Chiga (M)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Hiroaki Kikuchi (H)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Fumiaki Ando (F)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Takayasu Mori (T)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Eisei Sohara (E)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Shinichi Uchida (S)

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Naoki Sawa (N)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Kenmei Takaichi (K)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Yoshifumi Ubara (Y)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH